How Many Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s Analysts Are Bearish?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 3 analysts covering Arrowhead Research (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arrowhead Research had 4 analyst reports since June 18, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, June 18 report. FBR Capital maintained the stock with “Neutral” rating in Wednesday, August 8 report. Chardan Capital Markets maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Thursday, September 6 with “Buy” rating. On Thursday, September 6 the stock rating was upgraded by FBR Capital to “Buy”. Below is a list of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) latest ratings and price target changes.

06/09/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Buy Old Target: $17.5 New Target: $24.5 Maintain
06/09/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $18 Upgrade
08/08/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Neutral Old Target: $12 New Target: $18 Maintain
18/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $13.0000 Maintain

The stock increased 0.74% or $0.1 during the last trading session, reaching $13.63. About 1.56 million shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 456.10% since December 7, 2017 and is uptrending. It has outperformed by 440.48% the S&P500.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $1.20 billion. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Seekingalpha.com which released: “Arrowhead Pharmaceuticals – Here Come The Institutions And What That Could Mean – Seeking Alpha” on May 18, 2018, also Seekingalpha.com with their article: “Arrowhead Surges Forward With Major Deal And Its Intentions Were Highly Misunderstood – Seeking Alpha” published on October 08, 2018, Streetinsider.com published: “Arrowhead Pharma (ARWR) Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting – StreetInsider.com” on November 09, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: Nasdaq.com and their article: “Arrowhead Pharmaceuticals Inc. (ARWR) Has Risen To A New High On Study Data – Nasdaq” published on September 06, 2018 as well as Nasdaq.com‘s news article titled: “Detailed Research: Economic Perspectives on Arrowhead Pharmaceuticals, NexGen Energy, ArcBest, Cigna, The Allstate, and Comtech Telecommunications — What Drives Growth in Today’s Competitive Landscape – Nasdaq” with publication date: November 30, 2018.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.